With treatment, it is possible to alleviate the symptoms, control the complications of the disease, stabilize the patient’s condition, and slow the progression of multiple myeloma. Patients who do not show any symptoms may not need treatment.

However, the patient should be followed up with periodic blood and urine tests at regular intervals. If there are certain findings, if the disease progresses during the follow-up, treatment is started.

The treatment of lymph cancer is done by oncologists in Hematology-Oncology services. With modern chemotherapy, 70-80% of lymphoma patients can be cured.

The factors affecting the course of the disease are the stage of the disease, whether the patient responds to the treatment, the type of lymphoma, the recurrence of the lymphoma, whether there is diabetes or kidney disease together.

Chemotherapy drugs used in the treatment of lymphoma cancer can be administered alone or in various combinations. These drugs are used to eliminate cancer cells and prevent their proliferation.

Hodgkin lymphoma is manifested by enlarged lymph nodes. In some patients, Hodgkin lymphoma symptoms are seen as weight loss, night sweats, and recurrent fever. Computed tomography and bone marrow biopsy are usually required to determine the stage of the disease.

Hodgkin lymphoma is one of the cancer types with high treatment success today. At each stage, treatment is carried out by targeting the complete eradication of the disease.

There are some groups in the world that work to record advances in the treatment of Hodgkin lymphoma and carry out large-scale studies, one of which is the German Hodgkin Lymphoma Study Group (GHSG).

Risk factors are important in the patient-specific treatment of the disease. In patients with early stage and no bad risk factors, a short-term ABVD chemotherapy and radiation therapy is sufficient.

However, if the disease is advanced, a much more effective treatment (escalated BEACOPP protocol) may be required to completely eradicate the disease and prevent its recurrence. If it has relapsed, high-dose chemotherapy and autologous stem cell transplantation are often the best treatment option for complete eradication of the disease.

Leukemia describes a group of blood diseases characterized by the production and development of lymphocytes, a type of white blood cell (White blood cell) cells, which are responsible for body defense.

In order to treat leukemia, first of all, its type must be determined. A simple complete blood count detects signs of cancer in the blood. The diagnosis of leukemia is made due to the increase of cancer cells called blast in the blood.

The first method that comes to mind in the treatment of leukemia is chemotherapy. Chemotherapy drugs are chemical drugs that destroy cancer cells that cause leukemia.

The protein that gives blood its color and carries oxygen to the cells is called hemoglobin. Hemoglobin is carried by red blood cells (Red blood cells) in the blood. Anemia (anemia) is a condition in which the hemoglobin protein in the blood falls below the normal level or the number of red blood cells decreases.

Anemia treatment varies according to the type, course and severity of anemia. The main goal of treatment is to eliminate the condition that causes anemia. For Anemia caused by iron deficiency and folic acid, it is recommended to consume mainly green vegetables and fruits recommended by the physician.

It is also possible to do these with some supplements to be taken from outside. Vitamin supplements can be given with the help of drops or injections for Anemia due to B12 deficiency. If the anemia has progressed and reached a dangerous point, blood and marrow stem cell transplantation can be performed.

Mediterranean anemia (Beta thalassemia) patients need blood support every 3-4 weeks for life. The hemoglobin of the patient with thalassemia should be kept above 9.5 g/dl. In patients with thalassemia, complete blood count, blood iron level, heart, liver and hormonal system are evaluated regularly and attention is paid to blood-borne diseases.

If the annual blood consumption exceeds 1.5 times the normal, the spleen is surgically removed in advanced ages. Removal of the spleen reduces the need for blood, but is not a definitive solution.

Bone marrow transplantation is a treatment method that can completely correct Mediterranean anemia. Bone marrow transplantation from a healthy sibling with appropriate tissue type is successful, especially in well-treated patients with no liver damage.

However, in some cases, various serious problems may occur during or after bone marrow transplantation or the transplantation fails. On the other hand, gene transplantation, which is still being researched, is not yet applied to patients.

Multiple myeloma is the name given to a type of cancer that consists of a type of white blood cell called a plasma cell. It is a nasty disease caused by an uncontrolled increase of plasma cells. Plasma cells help fight infections by producing antibodies that recognize and attack microbes.

These antibodies are called immunoglobulins. The plasma cells that occur in multiple myeloma are also called myeloma cells. Myeloma cells produce abnormal antibodies called monoclonal. That is, instead of producing useful antibodies, plasma produces abnormal proteins that can cause complications.

Because multiple myeloma grows specifically in the bone marrow, it causes cancer cells to crowd out healthy bone cells. In asymptomatic cases, treatment is often not necessary. For cases that need treatment, a number of treatments are available to help control the disease.

Stem cell transplantation, or as it is commonly known, bone marrow transplantation is a method applied for the treatment of cancer and various diseases that cause changes in the blood and lymph system.

Granulocytes and monocytes, which form leukocytes that fight against diseases in the bone marrow, form young (blast) cells in the bone marrow.

These cells mature over time and play an important role in the immune system. As a result of the abnormality seen in the maturation period of young cells in the findings of acute myeloblastic leukemia, the cells that cannot continue their normal course can not fulfill their duties in the immune system together with the accumulation of cells in the blood and bone marrow. This clinical finding is called “Acute Myeloblastic Leukemia”.

Immune deficiency includes diseases that increase the susceptibility to infections caused by the deficiency of one or more cells, cell ligands, proteins, cytokines and cytokine receptors, and proteins necessary for intracellular warning systems of the immune system.

Since the definition of X-linked Agammaglobulinemia (XLA) by Bruton in 1952, more than 120 primary immune deficiencies have been defined due to the developments in technology, and the underlying molecular disorder has been identified in approximately 75% of them.

In a patient with suspected primary immunodeficiency, it is often possible to reach the diagnosis based on patient history, physical examination, and first-line laboratory investigations.

However, in any case, it is very important to detect the genetic defect at the molecular level. Thus, precise information about the disease, treatment approach, prenatal diagnosis and genetic counseling can be provided.